GSK's Promising Advances in Gynaecological Cancer Treatment

GlaxoSmithKline (GSK) has announced encouraging results from an early-stage trial of its new cancer treatment, Mocertatug Rezetecan, commonly referred to as Mo-Rez. The trial demonstrated that Mo-Rez successfully shrank or eliminated tumors in 62% of patients with ovarian cancer who had previously failed chemotherapy, and in 67% of patients with endometrial cancer. This treatment, an antibody-drug conjugate (ADC), was acquired from China’s Hansoh Pharma in late 2023 and has been tested on 224 patients globally, including in the UK. The drug is administered via intravenous infusion every three weeks, with only a few patients discontinuing treatment due to side effects, primarily nausea.

The Guardian

Under the leadership of Chief Executive Luke Miels, who took over on January 1, 2026, GSK is accelerating its drug development efforts. Miels, previously associated with AstraZeneca, has emphasized the need for "scientific courage" in advancing GSK's oncology portfolio. The company plans to initiate five late-stage clinical trials for Mo-Rez in the coming months, building on the positive data presented at the Society of Gynecologic Oncology’s annual meeting in Puerto Rico. Hesham Abdullah, GSK’s global head of cancer research and development, highlighted the urgent need for new therapies in gynaecological cancers, stating, “With Mo-Rez we now have compelling evidence of a promising clinical profile.”

The Guardian

Mo-Rez is projected to become a blockbuster drug, with anticipated peak annual sales exceeding £2 billion. This revenue is crucial for GSK as it aims to reach a sales target of £40 billion by 2031. The company has seen significant growth in its oncology division, which generated nearly £2 billion in sales last year, marking a 43% increase from 2024. The sales of Jemperli, an endometrial cancer drug, surged by 89%, indicating a robust demand for cancer treatments.

The Guardian

Despite these advancements, GSK's recent history in oncology has been tumultuous. The company divested its cancer portfolio to Novartis in 2015, only to re-enter the field a few years later under Miels' predecessor, Emma Walmsley. Critics may point to the challenges GSK faced in rebuilding its oncology capabilities, but the current trajectory suggests a renewed commitment to cancer research and development.

The Guardian

Miels has expressed a commitment to enhancing GSK's drug development pace, stating, “The entire organization is certainly really enjoying following this pace, the agility, and having the scientific courage.” Abdullah praised Miels' leadership, noting the strategic insight and engagement he brings to the organization.

The Guardian

• “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.” — Hesham Abdullah, GSK’s Global Head of Cancer Research and Development

The Guardian

• “His leadership style, the engagement, the strategic insight, the drug development expertise … you’re also seeing some of that come to life through the development programmes.” — Hesham Abdullah, GSK’s Global Head of Cancer Research and Development

The Guardian

GSK's advancements in gynaecological cancer treatments reflect a significant shift in its strategic focus and a potential turning point in its competitive standing within the pharmaceutical industry.

The Guardian